BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target
BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.
Stocks · News reference
Reported Earlier, Guardant Health Said The FDA Approved Guardant360 CDx As A Companion Diagnostic To Identify HR-positive, HER2-negative Advanced Or Metastatic Breast Cancer Patients With ESR1 Mutations Who May Benefit From Astrazeneca’s ETCAMAH (Camizestrant)
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.